THE USE OF INHALATION THERAPY IN RESPIRATORY DISEASES

Abstract

Inhalation therapy has emerged as a cornerstone in the management of respiratory diseases, offering targeted drug delivery to the respiratory tract with minimal systemic side effects. This article provides a comprehensive analysis of the use of inhalation therapy in treating conditions such as bronchial asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and pneumonia, as well as its role during the COVID-19 pandemic. Through a combination of literature review, statistical analysis, clinical case studies, and patient surveys, the article highlights the efficacy of inhalation therapy in improving symptom control, enhancing quality of life, and reducing disease exacerbations. Key findings indicate that inhalation therapy improves symptom control in 85% of asthma patients, reduces mucus viscosity by 50% in bronchitis cases, and alleviates respiratory symptoms in 70% of COVID-19 patients. However, challenges such as device handling errors, high costs, and individual intolerance remain significant barriers to its widespread adoption. The article also explores emerging innovations, including smart inhalers and nanoparticle-based drug delivery systems, which hold promise for improving adherence and therapeutic outcomes. By addressing these challenges and leveraging technological advancements, inhalation therapy is poised to play an even greater role in the future of respiratory care, offering hope for improved patient outcomes and accessibility.